Skip to content

Effect of an omega-3 fatty acid enriched lipid emulsion on acute respiratory distress syndrome (ARDS)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN63673813
Enrollment
16
Registered
2008-06-30
Start date
2000-08-10
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome (ARDS) Respiratory Respiratory failure, not elsewhere classified

Interventions

In the first 48 hours after the diagnosis of ARDS and before receiving artificial nutrition, patients were randomised into two different groups: Group A received the study emulsion Lipoplus® 20% (B.
50% MCT, 40% LCT, 10% omega-3) Group B received the control emulsion Intralipid® 20% (Fresenius Kabi
100% LCT) The lipid emulsions were administered during 12 hours at a rate of 0.12 g/kg/h. Measurements were made at baseline (immediately before the administration of lipid emulsions [t = 0]), at th

Sponsors

B. Braun Medical S.A. (Spain)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 - 85 years, either sex 2. ARDS in the first 48 hours of admission 3. Intolerance of enteral nutrition

Exclusion criteria

Exclusion criteria: 1. Aged younger than 18 or older than 85 years 2. Pregnancy 3. Liver failure 4. Human immunodeficiency virus (HIV) positivity 5. Leukopenia (less than 3500 mm^3) 6. Thrombocytopenia (less than 100,000 mm^3) 7. Severe renal insufficiency (creatinine greater than 6 mg/dl) or need for renal dialysis 8. Signs of heart failure 9. Transplantation 10. Multiple blood transfusions 11. Participation in other clinical trials simultaneously or in the last 60 days 12. Treatment with nitrous oxide or corticoids (prednisolone 2 mg/kg/d or equivalent) 13. Multiple organ failure 14. Severe dyslipidemia, or propofol treatment

Design outcomes

Primary

MeasureTime frame
1. Initial tolerance and security of an omega-3 fatty acid enriched lipid emulsion in patients with ARDS, evaluated during all the treatment period and up to the end of the ICU period 2. Effects on haemodynamics and respiratory function, measured at baseline, 6 hours, 12 hours (parenteral treatment ending), 24 hours (12 hours after parenteral ending)

Secondary

MeasureTime frame
Effects on eicosanoid synthesis, measured at baseline, 6 hours, 12 hours and 24 hours.

Countries

Spain

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Apr 4, 2026